LONDON – Four months from the referendum vote to leave the EU and – with the exception of a "commercially confidential" sweetheart deal with the Japanese car manufacturer Nissan – no company or sector is any clearer about the terms on which the U.K. government will seek to negotiate Brexit.
Avexis Inc. is preparing for a David-and-Goliath showdown with Biogen Inc. and its partner, Ionis Pharmaceuticals Inc., after the FDA green-lighted the design of a pivotal trial for the upstart's gene therapy candidate, AVXS-101, in infants and children with spinal muscular atrophy (SMA) type 1.
What a difference a few days and an FDA review can make. A week ago, Cempra Inc. (NASDAQ:CEMP) was trading just shy of $24. Wednesday, it closed at $7.30, down 60.9 percent in the company's heaviest day of trading ever.
Trillium Therapeutics Inc., of Toronto, said it advanced TTI-621, an SIRPa-IgG1 Fc fusion protein, from dose escalation into phase Ib cohort expansion enrollment in patients with advanced hematologic malignancies.
Celldex Therapeutics Inc., of Hampton, N.J., said it has inked an agreement to acquire privately held Kolltan Pharmaceuticals Inc., of New Haven, Conn.
Alkermes plc, of Dublin, reported that its total revenues for the third quarter of 2016 were $180.2 million compared to $152.7 million for the same period in 2015.
According to the American Heart Association’s website, “your heart muscle needs oxygen to survive. A heart attack occurs when the blood flow that brings oxygen to the heart muscle is severely reduced or cut off completely.”
PERTH, Australia – After completing its IPO in July, Sydney-based Noxopharm Pty Ltd. expects to have the first three clinical trials of its lead compound up and running in the first quarter of 2017.
RSS